RECURRENT GLIOSARCOMA
Clinical trials for RECURRENT GLIOSARCOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT GLIOSARCOMA trials appear
Sign up with your email to follow new studies for RECURRENT GLIOSARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to shrink returning brain tumors
Disease control Recruiting nowThis early-phase trial tests whether combining two drugs—atezolizumab (which helps the immune system attack cancer) and cabozantinib (which blocks cancer cell growth)—can safely shrink tumors in adults with glioblastoma that has returned after standard treatment. About 6 particip…
Matched conditions: RECURRENT GLIOSARCOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 04:00 UTC
-
Genetically modified immune cells take on deadliest brain tumor
Disease control Recruiting nowThis early-phase trial tests a new treatment for glioblastoma, a fast-growing brain cancer that has returned after standard therapy. Researchers give patients specially engineered natural killer (NK) cells from donated cord blood. These cells are modified to resist the tumor's de…
Matched conditions: RECURRENT GLIOSARCOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 03:56 UTC
-
New hope for aggressive brain tumors: drug combo shows promise before surgery
Disease control Recruiting nowThis study tests two drugs, GI-102 and pembrolizumab, given before surgery to people whose aggressive brain cancer (glioblastoma) has returned. The goal is to see if these drugs can shrink the tumor and help the immune system fight the cancer. About 36 adults will take part, and …
Matched conditions: RECURRENT GLIOSARCOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New drug duo takes on deadly brain tumor
Disease control Recruiting nowThis study tests two immunotherapy drugs, efineptakin alfa and pembrolizumab, in people whose glioblastoma has returned after standard treatment. The goal is to see if this combination can help the immune system attack the tumor and improve survival. About 54 adults with recurren…
Matched conditions: RECURRENT GLIOSARCOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
Cold virus turned against brain tumors in new trial
Disease control Recruiting nowThis early-phase trial tests a modified cold virus (DNX-2401) that targets and attacks brain cancer cells. The virus is loaded into donor stem cells and injected into an artery near the tumor. The study includes 36 adults with recurrent high-grade glioma and aims to find the safe…
Matched conditions: RECURRENT GLIOSARCOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:47 UTC